AIM
BNTC icon

Acrospire Investment Management’s Benitec Biopharma BNTC Stock Holding History

Acrospire Investment Management’s Portfolio BNTC Stock Details BNTC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-28
Closed -$13K – 194
2017
Q2 		$13K Buy
+28
New +$17.7K 0.01% 1713

Other funds holding BNTC

WS
Wedbush Securities Los Angeles, California $3.43B AUM 24.13% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Acrospire Investment Management's BNTC Position: Q3 2017 in Review

Acrospire Investment Management sold out of Benitec Biopharma (BNTC) in Q3 2017, closing a stake of 28 shares — an estimated $13K sold.

Acrospire Investment Management first reported a position in BNTC in Q2 2017 and held it in 1 quarter. The position peaked at $13K in Q2 2017. 3 funds tracked by Wall St. Rank hold BNTC as of Q3 2017.

  • Acrospire Investment Management reported no remaining Benitec Biopharma position as of Q3 2017 after selling out during the quarter.
  • Acrospire Investment Management sold 28 Benitec Biopharma shares in Q3 2017, an estimated $13K.
  • Acrospire Investment Management first reported a position in Benitec Biopharma in Q2 2017 and held it in 1 quarter.
  • Acrospire Investment Management's Benitec Biopharma position peaked at $13K in Q2 2017.
  • 3 funds tracked by Wall St. Rank held Benitec Biopharma as of Q3 2017.

Based on Acrospire Investment Management's 13F filing for Q3 2017, filed 26 Oct 2017.